Back to search results
NCT05292313

Dual Implant Versus Single Implant Distal End of Femur

Enrolling by Invitation
NAAges 60+InterventionalTreatment
University of Utah
~80 participants
Updated 2026-04-13 on ClinicalTrials.gov
What's tested:Single distal femur implantDual distal femur implants

At a glance

Recruiting sites
0 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Enrollment rate
Measured over 12-months, post-surgery
+3 more outcomes measured

Conditions

Distal Femur Fracture

Explore related trials

Femoral Fractures, Distal

NCT05292313

Where you'd take part

This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic

    Rochester, Minnesotano site contact published

  • New York University

    New York, New Yorkno site contact published

  • Oregon Health & Science Center

    Portland, Oregonno site contact published

  • University of Pittsburg Medical Center - Harrisburg

    Harrisburg, Pennsylvaniano site contact published

  • University of Utah Orthopaedic Center

    Salt Lake City, Utahno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Justin Haller, M.D. · PRINCIPAL_INVESTIGATOR · University of Utah Orthopaedics

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient age 60 years or greater,
Femur fracture distal to the femoral diaphysis,
Operative treatment within 72 hours of presenting to the treating hospital,
Patient was previously ambulatory,
Fracture amendable to either single or dual implant fixation,
Informed consent can be obtained from the patient, family member, or power of attorney,
Displaced fracture (\>2.5mm displacement, native or periprosthetic)

Exclusion

Associated major lower extremity fracture,
Ongoing infection,
History of metabolic bone disease (Paget's, etc),
Pathologic fracture,
Gustilo-Anderson Type 3B/3C open fractures,
Severe cognitive impairment (Six Item Screener with 3 or more errors),
Stage 5 Parkinson's disease,
Significant femoral bone loss requiring planned staged bone grafting,
Vascular injury,
Bilateral femur fractures,
Unable to follow-up at treating institution for 12 months

What this trial measures

  • Enrollment rate12-months, post-surgery

    Feasibility, defined by enrollment rate (80 patients across five sites)

  • Protocol adherence12-months, post-surgery

    Feasibility, defined by protocol adherence (≥90%)

  • Follow-up retention12-months, post-surgery

    Feasibility, defined by follow-up retention (≥85% at 12 months)

  • Data completeness12-months, post-surgery

    Feasibility, defined by data completeness (≥90%) for key secondary outcomes